You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

FLUD(PO)+R

Cancer Type: Hematologic, Leukemia - Chronic Lymphocytic (CLL)      Intent: Palliative
Regimen Category: Evidence-informed
Drugs Used:
riTUXimab (subcut) (PDRP prior authorization)
Funding:
New Drug Funding Program
    Rituximab - Previously Untreated Chronic Lymphocytic Leukemia
New Drug Funding Program
    Rituximab - Second Line - Chronic Lymphocytic Leukemia
ODB Limited Use
    fludarabine - For the first-line treatment of CLL in combination with rituximab (tablets; with or without cyclophosphamide)
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
New Drug Funding Program
    Rituximab (SC) - Previously Untreated Chronic Lymphocytic Leukemia

You might also be interested in